Icahn preps Forest lawsuit over succession; Redx creating new anti-infectives unit;

 @FierceBiotech: At GSK, there are no corner offices, or any other. More | Follow @FierceBiotech

 @JohnCFierce: Icahn step 5: Sue Forest over succession plan. More | Follow @JohnCFierce

> True to form, Carl Icahn is ramping up the pressure on Forest Laboratories as he pushes his second campaign to gain control of Forest Laboratories. Icahn says he is suing Forest over its succession plans. "Howard Solomon and this board, who collectively own less than 2 percent of this great company, must be made to realize that Forest Labs is not a dynasty to be despotically handed down from father to son," Icahn said in a letter. Icahn is once again seeking up to four seats on the board. Report

> The U.K.'s Redx Pharma is looking to hire up to 119 people as it builds a new division to develop anti-infectives. Report

> Oxford Biomedica is planning to raise £16 million to back the development of new eye disease drugs. Story

Medical Device News

 @FierceMedDev: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey  | Follow @FierceMedDev

> MHRA warns of reusable device contamination. Article

> FDA panel recommends against metal-on-metal hip implants. News

> FSS gets CE mark for self-expanding stent. Story

> Study: iPad use could muddle shunt settings. Study

Pharma News

 @FiercePharma: So, what's with all the drug names ending in "IQ"? Astellas' Myrbetriq, Arena's Belviq ... Did Pfizer's Pristiq start a trend? | Follow @FiercePharma

> FDA says yes to Astellas' bladder drug Myrbetriq. Article

> GSK again extends its $2.6 billion bid for HGS. Story

> Generic antiviral market poised to boom. More

> Icahn says CEO treating Forest like a dynasty. News

And Finally… Investigators in Brazil report that blocking the receptor of bombesin/gastrin-releasing peptide can improve survival in sepsis animal models. Release

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.